Engineered chimeric antigen receptor (CAR) immune cells successfully treat lymphomas; however, they are less efficient in targeting and eliminating solid tumors. Trafficking and ensuring their survival in the tumor microenvironment until all cancer cells are eliminated remains a challenge. In this webinar, experts will discuss advances that bring CAR therapy for solid tumors one step closer to reality.
Topics to be covered
•Engineering off-the-shelf CAR immune cells
•Improving the effectiveness of CAR T therapy with the gut microbiome
Tamara Laskowski, PhD
Scientific Project Director, CAR NK Program, Adoptive Cell Therapy Platform, Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center
Tamara Laskowski received her PhD in human molecular genetics and immunology from the University of Texas Health Science Center at Houston, where she researched targeted genome editing of patient stem cells to correct genetic mutations linked to immune disorders. Laskowski later joined Laurence Cooper’s laboratory at MD Anderson Cancer Center, where she developed stem-cell based platforms for off-the-shelf production of genetically modified natural killer and T cells. Subsequently, Laskowski transitioned to a senior scientist position at the Immunotherapy Platform led by James Allison and Padmanee Sharma, where her work focused on the application of multi-dimensional analytical approaches for comprehensive immune monitoring of clinical trials. Currently, Laskowski is a scientific project director in the CAR NK program at MD Anderson Cancer Center. In her role, she supports the development of novel off-the-shelf natural killer cell therapies targeting solid and hematological malignancies and the implementation of a multi-modal approach for product characterization and validation.
Maik Luu, PhD
Project Principal Investigator, University Hospital Würzburg, Scientific Project Manager, T2EVOLVE
Maik Luu received a PhD in immunology from the Philipps-University, Marburg and worked on the immunomodulatory activity of HDAC and proteasome inhibitors in carcinogenesis. Luu then worked as a postdoctoral associate in Michael Hudecek’s lab in Würzburg to investigate the role of bacterial metabolites on adaptive immunotherapies for cancer. Luu is a principal investigator at the University Hospital Würzburg and a scientific project manager at T2EVOLVE, an alliance of academic and industry leaders in cancer immunotherapy, under the European Union’s Innovative Medicine Initiative.